{"id":742618,"date":"2026-08-19T05:22:15","date_gmt":"2026-08-19T05:22:15","guid":{"rendered":"https:\/\/www.newsbeep.com\/uk\/742618\/"},"modified":"2026-08-19T05:22:15","modified_gmt":"2026-08-19T05:22:15","slug":"johnson-johnson-stock-jumps-3-as-healthcare-rotation-lifts-shares","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/uk\/742618\/","title":{"rendered":"Johnson & Johnson Stock Jumps 3% as Healthcare Rotation Lifts Shares"},"content":{"rendered":"\n

This article first appeared on GuruFocus<\/a>. <\/p>\n

Johnson & Johnson (NYSE:JNJ<\/a>), the healthcare heavyweight behind blockbuster medicines and medical technologies, surged<\/a> approximately 3% to $270.19 Tuesday morning as investors rotated out of high-growth technology stocks and into defensive companies. While the Nasdaq struggled with broad selling pressure, J&J pushed toward fresh 52-week highs as investors rewarded stability. <\/p>\n

The move comes as Johnson & Johnson continues to prove that size can still deliver growth. Second-quarter sales climbed<\/a> 6.6% to $25.31 billion, while adjusted earnings reached $2.90 per share. Management also raised its 2026 outlook, targeting approximately $101.1 billion in revenue and $11.68 in adjusted earnings per share at the midpoint. The company is now approaching a milestone few healthcare giants reach: surpassing $100 billion in annual sales. <\/p>\n

\"Johnson<\/a> Johnson & Johnson Stock Jumps 3% as Healthcare Rotation Lifts Shares \u00b7 us.finance.gurufocus <\/p>\n

But investors are paying a premium for that consistency. The GF Value chart shows J&J trading at $271.19 versus an estimated fair value of $192.38, meaning the stock sits roughly 41% above its GF Value. The market is clearly pricing in strong execution from its pharmaceutical pipeline, medical-device portfolio, and decades-long dividend record. <\/p>\n

The question is no longer whether Johnson & Johnson is a quality businessit clearly is. The bigger question is whether future growth can justify today’s valuation. With expectations already elevated, J&J will need continued pipeline wins, expanding earnings, and stronger innovation to keep investors chasing the stock after this defensive rally. <\/p>\n","protected":false},"excerpt":{"rendered":"This article first appeared on GuruFocus. Johnson & Johnson (NYSE:JNJ), the healthcare heavyweight behind blockbuster medicines and medical…\n","protected":false},"author":2,"featured_media":303934,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[43],"tags":[102,2960,5941,56,54,55],"class_list":["post-742618","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-health","tag-healthcare","tag-johnson-johnson","tag-uk","tag-united-kingdom","tag-unitedkingdom"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/742618","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/comments?post=742618"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/742618\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media\/303934"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media?parent=742618"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/categories?post=742618"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/tags?post=742618"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}